Browse by author
Lookup NU author(s): Dr Jane Renwick,
Professor Alan Boddy,
Dr Chris RedfernORCiD,
Professor Gareth Veal
Full text for this publication is not currently held within this repository. Alternative links are provided below where available.
Isomerisation to all-trans-retinoic acid (ATRA) is widely accepted as the key mechanism underlying the favourable clinical properties of 13-cis-retinoic acid (13cisRA). As intracellular metabolism of ATRA by CYP26 may result in clinical resistance to 13cisRA, an increase in efficacy may be achieved through modulation of this metabolic pathway. We have evaluated the effect of the CYP26 inhibitor R116010 on retinoid metabolism in neuroblastoma cell lines and a xenograft model. In neuroblastoma cells, which showed a high level of CYP26 induction in response to ATRA, R116010 selectively inhibited ATRA metabolism. In addition, siRNA-mediated knockdown of CYP26 selectively increased ATRA levels and the expression of retinoid-responsive marker genes was potentiated by R116010. Treatment of mice bearing SH-SY5Y xenografts with 13cisRA (100 mg kg-1) revealed substantial levels (16%) of intratumoral ATRA after 6 h, despite plasma ATRA levels representing only 1% total retinoids under these conditions. Co-administration of R116010 with 13cisRA in this mouse model resulted in significant increases in plasma ATRA and 13cisRA concentrations. Furthermore, R116010 induced significant decreases in levels of 4-oxo metabolites in hepatic tissue after co-administration with either ATRA or 13cisRA. These data suggest considerable potential for CYP26 inhibitors in the future treatment of neuroblastoma with 13cisRA. © 2007 Cancer Research.
Author(s): Armstrong J, Taylor GA, Thomas HD, Boddy AV, Redfern C, Veal GJ
Publication type: Article
Publication status: Published
Journal: British Journal of Cancer
Print publication date: 04/06/2007
ISSN (print): 0007-0920
PubMed id: 17486130
Altmetrics provided by Altmetric